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Close to acute heart failure, a restrictive and/or obstructive lung impairment can be detected in the 
absence of any primitive lung disease. To avoid diagnostic pitfalls, lung function evaluation should 
be delayed until after full patient recovery. http://bit.ly/3aEy8ed
Case history
A 59-year-old male former smoker, with a history of 
hypertension, diabetes and chronic ischaemic heart 
disease (prior non-ST-elevation myocardial infarction 
and percutaneous coronary intervention+stent 
on circumflex and descending anterior coronary 
arteries) was referred to our lab for progressive 
dyspnoea of unknown origin. Even if a temporary 
moderate left ventricular systolic dysfunction had 
been observed during the acute phase of non-ST-
elevation myocardial infarction, a cardiac ultrasound 
performed a few months after revascularisation 
showed a normal systolic function. At the time of 
the visit, the patient complained of a progressive 
functional capacity decline in the last 3 months, with 
shortness of breath after more than usual efforts 
(New York Heart Association class II). Pharmacological 
treatment included amlodipine, ivabradine, low 
dose diuretics, acetylsalicylic acid and metformin. 
At physical examination rhythmic pulse (70 bpm) 
and normal arterial pressure (120/70 mmHg) were 
detected, together with minimal dependent oedema, 
absence of jugular distention, bibasilar reduced 
breath sounds with rare fine crackles and soft cardiac 
tones with grade 2 holosystolic murmur. Resting ECG 
was normal, except for signs of a previous inferior 
myocardial infarction. Resting pulmonary function 
test (PFT) showed a severe restrictive deficit with 
moderate reduction in lung diffusion for carbon 
monoxide (DLCO) entirely due to a reduction in the 
alveolar volume (VA). A maximal cardiopulmonary 
exercise test (CPET) showed a severe reduction 
in exercise capacity with ventilatory limitation 
to exercise and a restrictive ventilatory pattern. 
However, further investigations led to diagnosis of 
heart failure. Indeed, a chest radiograph (figure 1) 
showed vascular congestion and pleural effusion, 
cardiac ultrasound showed a severe reduction in 
left ventricular systolic function (23.5%) with left 
ventricular dilation, increased left ventricular filling 
pressure and pulmonary hypertension and brain 
natriuretic peptide (BNP) was significantly altered 
(579 pg·mL−1). A primary lung disease was excluded 
by computed tomography lung scan.
Question
What is the best timing to perform PFTs in the 
context of heart failure?
Answer
Although symptoms and clinical signs were not 
specific, heart failure diagnosis became clear 
after further diagnostic analysis. In this context, 
however, PFT showed a restrictive ventilatory deficit 
suggesting lung disease comorbidity. Moreover, 
CPET identified a ventilatory and not a cardiac 
limitation to exercise.
In table 1, the results of PFT and CPET 
are reported. Forced vital capacity (FVC) was 
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significantly reduced (1.72 L, corresponding to 
42% of the predicted value in a 172 cm tall male 
with a body mass index of 32.8 kg·m−2), as well 
as forced expiratory volume in 1 s (FEV1), but with 
a FEV1/FVC ratio of 0.87 which is not consistent 
with an obstructive disease. Even in the absence 
of plethysmographic data, a prevalent restrictive 
disease was highly likely if the severe reduction 
in the VA and the shape of the flow–volume loop 
are taken into account. DLCO, measured by single 
breath technique, appeared to be severely reduced 
(13.4 mL·mmHg−1·min−1, 49% of the predicted 
value), especially after correction for haemoglobin 
level (17.1 g·dL−1), and was entirely accounted 
for by the reduction in VA (38% of the predicted 
value). Accordingly, DLCO/VA was higher than 
expected. This is consistent with a diagnosis of 
restrictive lung disease as well. A severe reduction in 
exercise capacity was also observed, with a maximal 
workload of only 54 W and a test duration <5 min in 
a ramp test set at 12 Watts per minute. Even if the 
patients subjectively performed a maximal exercise 
test, the test was submaximal from a “metabolic” 
point of view, as shown by a peak respiratory 
exchange ratio (RER) (carbon dioxide production 
(V′CO2)/oxygen uptake (V′O2)) <1.1. Accordingly, peak 
V′O2 was severely reduced (11.4 mL·Kg−1·min−1, 
corresponding to a Weber class C and 48% of 
the predicted value). Anaerobic threshold (AT), 
calculated by the inflection point in the V′CO2/V′O2 
relationship was anticipated (9.3 mL·Kg−1·min−1, 
32% of the maximal predicted V′O2) (figure 2a). 
Nevertheless, the rate of increase in V′O2 with 
workload (ΔV′O2/ΔWork slope) was normal and 
not consistent with a cardiogenic limitation. Peak 
O2 pulse was reduced as well (9.4 mL·beat−1, 63% 
of the predicted); however, this finding cannot be 
considered as a marker of inadequate increase of 
systolic volume with exercise as a plateau is absent 
and the test is largely submaximal. In figure 3, O2 
pulse behaviour during exercise is shown both in 
pre- and post-treatment CPETs. However, the most 
obvious CPET anomaly observed is the ventilation 
response to exercise. Some degree of ventilation 
inefficiency was outlined by a V′E/V′CO2 slope slightly 
above the normal limit, which usually indicates an 
increase in dead space (VD) ventilation. Of interest, 
V′E/V′CO2 ratio at the AT and nadir V′E/V′CO2 were 
both elevated and higher before (45 and 41, 
respectively) than after treatment (41 and 31 
respectively), as detailed in table 1. Accordingly, 
measurement of VD/tidal volume (VT) course 
during CPET would have been of great help in the 
test interpretation, but it would have required serial 
arterial sample collection for blood gas analysis 
during exercise, which is not routinely performed. 
Presence of a lung disease could be even inferred 
by the increase in the y-intercept of the V′E/V′CO2 
relationship, that was as high as 7.6 L (figure 4a). 
This value, which is usually <3 L in normal 
subjects, represents the amount of ventilation at 
a hypothetic null V′CO2, roughly representing VD 
Figure 1 Chest radiograph clearly showing the presence of lung vascular congestion and 
pleural effusion.
Table 1 Main CPET and PFT results from tests performed
Variables Pre-heart 
failure 
treatment
Post-heart 
failure 
treatment
CPET
 Peak V′O2 mL·Kg−1·min−1 11.4 19.4
 Peak V′O2 % predicted 48 76
 ΔV′O2/ΔWork mL·min−1·W−1 10.3 10.4
 Peak O2 pulse mL·beats−1 9.4 13.4
 Max workload W 54 121
 V′E/V′CO2 slope 33 28
 V′E/V′CO2 at AT 45 33
 V′E/V′CO2 nadir 41 31
 Peak V′E L·min−1 50 78
 Peak respiratory rate breaths·min−1 54 42
 Breathing reserve % 3 14
 Peak SpO2 % 89 95
 Peak RER 0.91 1.24
PFT
 FVC L 1.72 3.23
 FVC % predicted 42 77
 FEV1 L 1.50 2.59
 FEV1 % predicted 47 81
 FEV1/FVC 0.87 0.80
 DLCO mL·mmHg−1·min−1 13.4 22.4
 DLCO % predicted 49 82
 DLCOadj mL·mmHg−1·min−1 12.6 21.0
 DLCOadj % predicted 46 77
 DLCOadj/VA mL·mmHg−1·min−1·L−1 5.22 5.04
 DLCOadj/VA % predicted 119 117
 VA L 2.56 4.44
 VA % predicted 38 67
SpO2: arterial oxygen saturation measured by pulse oximetry; RER: respiratory 
exchange ratio; DLCOadj: DLCO adjusted after correction for haemoglobin level.
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ventilation. More importantly, a near complete 
erosion of breathing reserve (3%, 1.8 L) at the 
peak exercise was recorded. A ventilatory limitation 
to exercise is usually stated when breathing 
reserve is <10% or 11 L as an absolute value. 
Breathing reserve is calculated as the difference 
between the maximal voluntary ventilation and 
actual maximal ventilation. In this case maximal 
voluntary ventilation was not directly measured, 
but it was calculated by FEV1 (maximal voluntary 
ventilation=FEV1×35=1.50×35=52.5 L·min−1; 
breathing reserve=52.5–50.7)/52.5×100=3.4%). 
Patient inability to adequately increase VT 
during exercise also translated into an elevated 
peak respiratory rate (RR) (54 acts·min−1). The 
pathological ventilatory pattern during exercise, 
consistent with restrictive lung impairment, is 
well depicted by the relationship between the 
increase in VT and V′E (figure 5b). Even in the very 
first part of exercise, ventilation increases almost 
exclusively thanks to an increase in RR, with 
only trivial increase in VT. Moreover, conversely 
to what usually happens in obstructive lung 
disease, end-tidal carbon dioxide tension was 
below the upper limit throughout the whole 
exercise (maximal end-tidal carbon dioxide tension 
32.1 mmHg). Finally, a significant O2 desaturation 
was detected (arterial oxygen saturation measured 
by pulse oximetry from 95% to 89% at the peak), 
which is typically observed in lung diseases, but 
only rarely in heart failure.
Follow-up
The patient was treated with i.v. diuretic and 
inotropic therapy obtaining almost complete 
resolution of heart failure signs and symptoms, 
BNP reduction (245 pg·mL−1) and pleural effusion 
disappearance. Before hospital discharge, PFT 
and CPET were repeated. As shown in table 1, 
PFT displayed an almost normalised FVC (77% 
of predicted) (figure 5a) and DLCO and a dramatic 
improvement in maximal exercise capacity at CPET 
(peak V′O2 19.4 mL·Kg−1·min−1, 76% of predicted 
value, AT 46% of maximal V′O2 predicted) (figure 2b). 
Exercise was now maximal even from a metabolic 
point of view (peak RER 1.24). V′E/V′CO2 slope was 
normalised and the y-intercept was significantly 
reduced (figure 4b). Breathing reserve was now 14%, 
with an increased peak ventilation (78 L·min−1) and 
a reduced peak RR (42 breaths·min−1). Ventilatory 
pattern during exercise, even if still abnormal, 
greatly improved, with a steeper increase in VT with 
exercise (figure 5b). Oxygen desaturation was no 
more detectable. Of interest, O2 pulse increased 
when compared to pre-therapy CPET (from 9.4  to 
13.4 mL·beat−1).
Only lung function investigations performed 
once heart failure was completely resolved were 
able to correctly describe the clinical picture of the 
patient.
Discussion
The present case shows that, in a patient with 
severe heart failure, PFT and CPET may mimic 
severe lung disease, if tests are performed closely 
to the acute phase. Indeed, we observed a severe 
restrictive pulmonary pattern, low DLCO and low 
VA at rest coupled with low breathing reserve and 
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Figure 2 AT identification by a V-slope (V′CO2 versus V′O2) graph. The change in the slope 
(dotted line) identifies the appearance of V′CO2 surplus by anaerobic metabolism. The threshold 
is clearly anticipated in a) the test performed close to acute cardiac decompensation versus b) the 
pre-discharge test. Dotted lines show a) AT=9.3 mL·Kg−1·min−1 (32% V′O2max predicted) and b) 
AT=11.8 mL·Kg−1·min−1 (46% V′O2max predicted).
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Figure 3 a) Pre- and b) post-heart failure treatment O2 pulse curves showing no change in 
slope morphology. Of note in (a), pre-treatment CPET showed a shorter exercise due to ventila-
tory limitation.
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Figure 4 V′E/V′CO2 slope a) pre- and b) post-heart failure treatment tests. In the first test, both 
a higher slope and y-intercept value are detectable. a) Slope=33, y=7.6 L. b) Slope=28, y=5.6 L.
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haemoglobin desaturation during exercise. All are 
considered signs of pulmonary disease and exercise-
induced ventilatory limitation. Otherwise treatment 
was guided by cardiac ultrasound, BNP, chest 
radiography and clinical findings. After heart failure 
treatment, the respiratory abnormalities almost 
disappeared. However, it should be underlined 
that some clues could have been identified at 
CPET, possibly suggesting a cardiogenic origin to 
the functional limitation. In particular, V′E/V′CO2 at 
and nadir V′E/V′CO2 were elevated and improved after 
heart failure therapy. These findings could suggest a 
pulmonary vascular involvement as a contributor to 
pulmonary inefficiency, possibly due to heart failure 
underlining the importance of a comprehensive 
evaluation of CPET parameters in order to avoid 
misdiagnosis.
Dyspnoea and fatigue are cardinal symptoms of 
both cardiac and lung diseases. Frequently, these 
pathologies co-exist worsening clinical condition 
[1–4] and making it difficult for physicians to 
correctly identify the cause of dyspnoea and 
reduced exercise capacity [5]. A wide amount 
of evidence suggests that CPET, in conjunction 
with PFT, is a useful clinical tool to identify 
cardiac and/or pulmonary causes of dyspnoea 
of unclear or multifactorial origin [6]. As a rule, 
cardiovascular disorders are characterised by low 
V′O2 and O2 pulse at peak exercise, an abnormal 
ΔV′O2/ΔWork relationship and normal breathing 
reserve. Low peak V′O2 together with low breathing 
reserve, lack of VD/VT reduction during exercise and 
normal ΔV′O2/ΔWork relationship are observed 
in the case of ventilatory limitation to exercise 
[7]. The y-intercept of the V′E/V′CO2 relationship 
is also of help, being normal in the absence of 
lung disease and elevated when the presence 
of lung disease induces an increase in VD during 
exercise [8]. However, it is important to be aware 
of possible diagnostic pitfalls. Advanced heart 
failure may be associated with some amount 
of lung restriction [9], frequently neglected in 
clinical practice, mainly because in most cases 
it doesn’t compromise accuracy in identifying 
exercise limitation. The close relationship between 
cardiac and pulmonary pathophysiology was first 
described in 1785 by Withering and in 1883 by 
Hope, who coined the term “cardiac asthma” [10]. 
Moreover, several studies showed a reduction in 
FEV1, FVC and DLCO in heart failure [11]. Several 
factors may be responsible for restrictive lung 
pattern in heart failure such as increased lung 
stiffness due to alveolar effusion, reduction of 
working alveolar–capillary units [12], respiratory 
muscle fatigue [13], cardiac enlargement [14] and 
constriction of under perfused alveoli leading to 
reduced lung compliance in a low cardiac output 
state [15]. However, evidence in this field is not 
extensive and pathophysiology regulating heart-
lung interactions is complex and not completely 
cleared. This is particularly true in the set of acute 
or sub-acute HF, when pulmonary congestion 
and pleural effusion could cause both restrictive 
and obstructive lung deficiency [16]. A good rule 
is to refrain from performing pulmonary function 
evaluation (both PFT and CPET) during or soon after 
the acute phase of heart failure. This evaluation 
becomes very useful in pre-discharge conditions, 
when the correct identification of heart failure 
comorbidities is pivotal for the choice of the most 
suitable pharmacological treatment [17].
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Figure 5 a) The resting maximal expiratory flow–volume loops in acute conditions (line a) and 
at the pre-discharge evaluation (line b) are shown. At the first evaluation, an obvious reduc-
tion in FVC was recorded. b) The relationship between increase in VT and V′E during exercise is 
reported. Solid lines indicate points with the same RR. In the first CPET (1) there is an almost 
complete lack of increase in VT, and V′E increase is entirely due to increase in RR. This pattern 
greatly improved in the pre-discharge test (2).
Self-evaluation questions
1. In a patient with lung restrictive disease which of the following CPET 
results is more likely?
a. A steep increase in VE/V′CO2 slope throughout the whole exercise
b. A poor increase in VT and an inappropriate increase in RR already in 
the early phase of exercise
c. A very high breathing reserve at the end of exercise
2. HF can cause a restrictive lung pattern by which of the following 
mechanisms?
a. Cardiac enlargement, increased pulmonary stiffness, reduction in 
working alveolar–capillary units and respiratory muscle fatigue
b. Cardiac enlargement, anaemia and increased lung stiffness
c. Respiratory muscle fatigue, increased lung stiffness and reduced 
venous pulmonary pressure
3. In the context of HF, CPET usually shows:
a. Normal ΔV′O2/ΔWork slope, reduced peak oxygen pulse, delayed AT 
and preserved VD/VT reduction during exercise
b. Reduced ΔV′O2/ΔWork slope, reduced peak oxygen pulse, early AT 
and preserved VD/VT reduction during exercise
c. Normal ΔV′O2/ΔWork slope, reduced peak oxygen pulse, early AT 
and inadequate VD/VT reduction during exercise
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Key points
●● Lung function evaluation is pivotal in the diagnostic assessment of heart failure, as lung disease 
comorbidities influence both prognosis and therapy
●● A restrictive or obstructive lung impairment can be identified that is solely due to cardiac 
decompensation in the absence of any primitive lung disease, especially in the acute or subacute 
phases of heart failure
●● Accordingly, lung function tests should not be performed prior to complete restoration of acute 
heart failure; however, a pre-discharge complete lung function evaluation is highly advisable 
in most patients
